Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.65 |
| ▸ | GNRHR | P30968 | 19/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7542580 | 1.00 | CACNA1B (0.65) | CACNA1BGNRHRCYP3A4 | |
| SCHEMBL7549514 | 0.91 | CACNA1B (0.66) | CACNA1BGNRHRCYP3A4 | |
| SCHEMBL7549508 | 0.91 | CACNA1B (0.66) | CACNA1BGNRHRCYP3A4 | |
| SCHEMBL8079362 | 0.89 | CACNA1B (0.50) | CACNA1BGNRHR | |
| SCHEMBL7543696 | 0.89 | CACNA1B (0.50) | CACNA1BGNRHR | |
| SCHEMBL7545821 | 0.86 | CACNA1B (0.73) | CACNA1BGNRHRCYP3A4 | |
| SCHEMBL7545829 | 0.86 | CACNA1B (0.73) | CACNA1BGNRHRCYP3A4 | |
| SCHEMBL7544412 | 0.86 | CACNA1B (0.49) | CACNA1BGNRHR | |
| SCHEMBL7544420 | 0.86 | CACNA1B (0.49) | CACNA1BGNRHR | |
| SCHEMBL7541511 | 0.80 | GNRHR (0.68) | CACNA1BGNRHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027046-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | disclosed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| US-6159989-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 2000-12-12 | — | — | US | disclosed |
| EP-1027046-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6017944-A | TREATING A VARIETY OF SEX-HORMONE RELATED AND OTHER CONDITIONS IN BOTH MEN AND WOMEN; PREVENTING PREGNANCY, TREATING LUPUS ERYTHEMATOSIS, IRRITABLE BOWEL SYNDROME, PREMENSTRUAL SYNDROME, HIRSUTISM, SLEEP DISORDERS | MERCK & CO., INC. (US) | 2000-01-25 | — | — | US | disclosed |
| WO-1999021553-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | CACNA1B 3/4885GNRHR 1315/4885CYP3A4 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.